Harmony Biosciences Net Receivables Over Time

HRMY Stock  USD 34.71  0.64  1.88%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Harmony Biosciences Performance and Harmony Biosciences Correlation.
  
Net Receivables is likely to rise to about 77.8 M in 2024.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harmony Biosciences. If investors know Harmony will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harmony Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.254
Earnings Share
2.11
Revenue Per Share
11.923
Quarterly Revenue Growth
0.161
Return On Assets
0.1285
The market value of Harmony Biosciences is measured differently than its book value, which is the value of Harmony that is recorded on the company's balance sheet. Investors also form their own opinion of Harmony Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Harmony Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harmony Biosciences' market value can be influenced by many factors that don't directly affect Harmony Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harmony Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Harmony Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harmony Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Net Receivables Analysis

Compare Harmony Biosciences and related stocks such as Keros Therapeutics, Janux Therapeutics, and Fennec Pharmaceuticals Net Receivables Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
KROS922 K922 K922 K922 K922 K922 K922 K922 K922 K922 K216 K18 M841 K1.1 MM
JANX0.00.00.00.00.00.00.00.00.00.0M200 K700 K2.2 M1.8 M
FENC29.9 K0.00.00.00.00.00.00.00.00.00.00.01.5 M8.8 M9.3 M
EWTX548 K548 K548 K548 K548 K548 K548 K548 K548 K548 K548 K548 K251 K225.9 K319.6 K
PLRX250 K250 K250 K250 K250 K250 K250 K250 K500 K7.4 M9.4 MMMM3.8 M
SNDX35 K35 K35 K35 K35 K258 K306 K377 K253 K116 K175 K429 K4.1 M1.2 M795.6 K
RVMD7.3 M7.3 M7.3 M7.3 M7.3 M7.3 M7.3 M7.3 M7.3 M8.7 M6.4 M5.9 M4.7 M1.3 M1.2 M
VRDN1.2 M1.2 M1.2 M994 K1.1 M394 K524 K1.5 M24 K108 K451 K451 K102 K91.8 K87.2 K
INZY31 K31 K31 K31 K31 K31 K31 K31 K31 K104 K155 K62 K115 K385 K404.2 K
VTYX60 K60 K60 K60 K60 K60 K60 K60 K60 K60 K60 K60 K96 K800 K840 K
NUVL3.2 M3.2 M3.2 M3.2 M3.2 M3.2 M3.2 M3.2 M3.2 M3.2 M3.2 M3.2 M4.5 M5.1 M4.2 M
TVTXMMMMM59.3 M65.4 M13.9 M14.5 M18 M33.1 M15.9 M16.6 M21.2 M21.3 M
REPL1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M2.4 M2.5 MMM3.1 M2.9 M4.9 M3.2 M
LYRA167 K167 K167 K167 K167 K167 K167 K167 K167 K167 K167 K167 K167 K150.3 K133.6 K
KRON198 K198 K198 K198 K198 K198 K198 K198 K198 K198 K612 K816 K572 K657.8 K604.5 K
GOSS500 K500 K500 K500 K500 K500 K500 K500 K500 K1.5 M200 K200 K200 K180 K171 K
IDYA1.9 M1.9 M1.9 M1.9 M1.9 M1.9 M1.9 M1.9 M1.9 M1.9 M1.9 M1.1 M211 K18 K17.1 K
PTGX523 K523 K523 K523 K523 K715 K2.2 M3.2 MM6.8 M2.4 M1.6 M52 K10.3 M10.8 M
VRNA3.4 K141.3 K107.2 K107.2 K1.4 M5.9 M1.1 M5.7 M7.1 M9.8 M8.3 M15.6 M9.3 M11 M11.5 M

Harmony Biosciences and related stocks such as Keros Therapeutics, Janux Therapeutics, and Fennec Pharmaceuticals Net Receivables description

My Equities

My Current Equities and Potential Positions

Harmony Biosciences Holdings
HRMY
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationPennsylvania; U.S.A
ExchangeNASDAQ Exchange
USD 34.71

Additional Tools for Harmony Stock Analysis

When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.